Generate a tailored SOP for Dr. Jan Stenvang. Improve your application with a focused, well-structured draft.
Jan Stenvang is an Associate Professor in Translational Clinical Pharmacology at the University of Copenhagen. With a background in molecular biology and biochemistry, his research primarily focuses on colorectal and breast cancer. He has over 15 years of experience in basic research and translational science, particularly in drug resistance and biomarker discovery. Stenvang has led projects that explore the mechanisms of cancer resistance, contributing to both academic and industrial collaborations aimed at improving cancer treatment outcomes. His lab has developed a research platform that utilizes drug-sensitive and drug-resistant cancer cell lines to identify predictive biomarkers for therapeutic responses. Notably, Stenvang's studies have shown that certain antihistamines may synergize with chemotherapy and enhance treatment efficacy. In addition, he has been involved in the development of novel compounds like LMP-400, which targets topoisomerase-I in resistant colorectal and breast cancer models. His ongoing clinical trials are focused on anti-cancer drug re-purposing guided by predictive biomarkers, aiming to refine treatment strategies for colorectal and breast cancer patients.
Focuses on clinical, social, and cognitive psychology.